Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in Qatar
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02175537|
Recruitment Status : Completed
First Posted : June 26, 2014
Last Update Posted : December 19, 2014
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type II Overweight and Obesity Hypertension Behavioral Lifestyle Change Social Change||Behavioral: Microclinic Social Induction Diabetes and Obesity Program||Not Applicable|
This pilot study, "Microclinic Social Induction Intervention for Diabetes and Obesity Management in Qatar," is a two-arm randomized controlled trial of a 7-week condensed intervention to evaluate the efficacy of the microclinic social induction model on propagating lifestyle changes and in improving glycemic and metabolic control in Doha, Qatar.
The microclinic social induction model leverages different levels of social and familial relationships to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called 'microclinic groups,' consisting of 2-8 peers and family members of the same social network. The intervention model brings microclinic groups to a larger classroom network (~25 people/class) where each class shares access to a culturally salient diabetes educational curriculum and group support to promote health behavior changes such as improvement in diet, exercise, medication adherence, and blood pressure management to then influence better glycemic and metabolic control.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||64 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in Qatar|
|Study Start Date :||June 2014|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
Experimental: Microclinic social induction training
BMI of 30 and over; or BMI of 25 and over and self-reported pre-diabetes or type II diabetes will receive the Microclinic Social Induction Diabetes and Obesity Program. The intervention is a training on diabetes self-management, disease monitoring, diabetes prevention, prevention of complications, health behavior change, and social network supports in order to improve chronic disease risk factors.
Behavioral: Microclinic Social Induction Diabetes and Obesity Program
Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
No Intervention: Controls
Receiving no intervention but parallel primary and secondary outcome measures as intervention study arm
- Weight [ Time Frame: Weekly measurements between baseline and end of trial after 7 weeks ]Change in body weight (and BMI)
- HbA1c [ Time Frame: Baseline, end of trial after 7 weeks ]Change in HbA1c from baseline to end of 7-week pilot phase.
- Waist circumference [ Time Frame: Baseline, 4th-week midpoint, 7th-week final ]
- Blood Pressure [ Time Frame: Baseline, 4th-week midpoint, 7th-week final ]Systolic and diastolic blood pressure changes
- Health Profile Survey [ Time Frame: Baseline, end of trial after 7 weeks. ]Change in overall health seeking and health maintenance behaviors.
- Social Network Relationships [ Time Frame: Baseline, end of trial after 7 weeks. ]Changes in degree of interpersonal health support relationships as assess on Social Network Matrix instrument
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02175537
|Qatar Diabetes Association|
|Principal Investigator:||Eric L Ding, PhD||Harvard School of Public Health|
|Principal Investigator:||Daniel Zoughbie, DPhil||Microclinic International|